UPDATE: Incyte (INCY) Tops Q3 EPS by 12c, Beats on Revenues; Boosts FY17 Jakafi Net Product Revenue Guidance
Get Alerts INCY Hot Sheet
Price: $52.35 -0.89%
EPS Growth %: +132.4%
Financial Fact:
Basic (in shares): 188.03M
Today's EPS Names:
MAXN, CSTR, ACU, More
EPS Growth %: +132.4%
Financial Fact:
Basic (in shares): 188.03M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
(Updated - October 31, 2017 7:09 AM EDT)
Incyte (NASDAQ: INCY) reported Q3 EPS of $0.17, $0.12 better than the analyst estimate of $0.05. Revenue for the quarter came in at $381.53 million versus the consensus estimate of $359.7 million.
- $304 million of 2017 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 36 percent growth over the same period last year
- Progress across the portfolio as multiple candidates enter late-stage development trials
- Two recent collaborations further expand potential and scope of Incyte’s combination immunotherapy development activities
For earnings history and earnings-related data on Incyte (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Growth isn't weak enough to truly undercut inflation pressures - BMO
- Netflix (NFLX) raised to Buy at Needham & Company on revenue upside
- Parke Bancorp (PKBK) Reports Q1 EPS of $0.51
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!